Autologous Transplantation for Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research is to learn if treatment with high-dose busulfan and
cyclophosphamide plus autologous bone marrow transplantation followed by treatment with
Gleevec (imatinib mesylate) is effective in treating chronic myelogenous leukemia (CML).
Objectives:
1. To assess the efficacy of high dose busulfan-cyclophosphamide and autologous
hematopoietic transplantation with post transplant Imatinib mesylate for the treatment
of CML. The primary endpoint of the study is to determine the proportion of patients
with CML alive in cytogenetic remission at one year following this treatment.
2. Secondary endpoints are time to progression and survival.